Letrozole

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

来曲唑（INN，商品名 Femara）是一种口服非甾体芳香酶抑制剂，已被引入用于激素反应性乳房的辅助治疗 Y 雌激素是通过芳香酶的活性将雄激素转化而产生的。

Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast Y Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. (In Vitro):Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner.Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation.Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells(In Vivo):Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats.

Letrozole (0.1-100 nM; 24-96 h) significantly inhibits growth of the MCF-7 epithelial breast cancer cells in a dose- and time-dependent manner.Letrozole (10 nM) significantly suppresses the stimulatory effects of testosterone on MCF-7 cell proliferation.Letrozole (10 nM; 24-48 h) suppresses the levels of secreted metalloproteinases (MMP‐2 and MMP‐9) in MCF-7 cells. Cell Viability Assay Cell Line:MCF-7 cells Concentration:0.1, 1, 10, 100 nM Incubation Time:24, 48, 96 hours Result:Inhibited cells growth in a dose- and time-dependent manner.

Letrozole (3-300 μg/kg; oral gavage once daily for 6 weeks) exhibits anti-tumor effects in rats. Animal Model:Adult female rats bearing mammary tumorsDosage:3, 10, 30, 100, 300 μg/kg Administration:Oral gavage once daily for 6 weeks Result:Induced complete regression of mammary tumors, with an ED50 of 10-30 μg/kg/day.

CGS 20267

Endocrinology/Hormones

Aromatase

Aromatase

Cancer

——

112809-51-5

285.3

C17H11N5

>98% (HPLC)

DMSO: 57 mg/mL (199.78 mM)

N#CC1=CC=C(C(C2=CC=C(C#N)C=C2)N3N=CN=C3)C=C1

4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile

(-20℃)

With Ice Pack

≥ 2 years